A recent study highlights the use of guselkumab as an effective adjunct treatment for pyoderma gangrenosum, while successfully maintaining clinical remission in patients with ulcerative colitis. This finding could influence treatment strategies for patients suffering from these conditions.
guselkumab as a treatment adjunct for pyoderma gangrenosum while maintaining clinical remission of ulcerative colitis
Original title: “Guselkumab as a Treatment Adjunct for Pyoderma Gangrenosum While Maintaining Clinical Remission of Ulcerative Colitis.”